Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC

Charles Rudin MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY discusses targeted therapies, immunotherapy and their combination in non-small cell lung cancer (NSCLC) therapy. Targe... Author: VJOncology Added: 02/14/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts